PYOTT DAVID E I sold $274K of ALNY
PYOTT DAVID E I sold 921 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $297.71 ($0.27M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
This provides a datapoint on director ownership but does not introduce new operational or clinical information.
Market read
Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 structure and small size reduce expected fundamental impact.
What to watch
The sale size is modest (921 shares) and the plan is pre-arranged, so the market may discount it; liquidity/positioning effects may matter more than fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Alnylam Pharmaceuticals, Inc. (ALNY).
Ticker impact
A director of Alnylam sold 921 shares in an open-market transaction disclosed via SEC Form 4 on June 1 under a 10b5-1 plan.
Likely limited/short-lived impact; any reaction should fade unless accompanied by other fundamental news.
The filing is an ownership-change disclosure (not an earnings/drug/contract event) and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market effects
Minimal; this is company-specific insider activity without new biotech/clinical read-through.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated or unusually large sales can be interpreted by some traders as confidence erosion—watch for follow-on filings.
Key entities
- public_companyALNY
Alnylam Pharmaceuticals, Inc.; subject of the insider transaction disclosure.
- insiderPYOTT DAVID E I
Director who sold 921 shares in an open-market transaction under a 10b5-1 plan.
